| 2026-03-30 |
详情>>
内部人交易：
Pisano Christopher A股份增加200000.00股
|
| 2026-03-10 |
详情>>
股本变动：
变动后总股本4797.38万股
|
| 2026-03-10 |
详情>>
业绩披露：
2025年年报每股收益0.25美元,归母净利润1124.79万美元,同比去年增长151.15%
|
| 2026-03-09 |
财报披露：
美东时间 2026-03-09 盘后发布财报
|
| 2025-11-17 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.18美元,归母净利润-793.92万美元,同比去年增长62.38%
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益-0.05美元,归母净利润-224.32万美元,同比去年增长85.24%
|
| 2025-05-06 |
详情>>
业绩披露：
2025年一季报每股收益0.01美元,归母净利润60.82万美元,同比去年增长108.06%
|
| 2025-04-28 |
股东大会：
将于2025-06-13召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified;
2.To ratify the selection of CBIZ CPAs, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-03-11 |
详情>>
业绩披露：
2024年年报每股收益-0.53美元,归母净利润-2198.8万美元,同比去年增长7.23%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.52美元,归母净利润-2110.51万美元,同比去年增长-9.96%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-0.38美元,归母净利润-1519.71万美元,同比去年增长-23.61%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.19美元,归母净利润-754.49万美元,同比去年增长-57.68%
|
| 2024-04-29 |
股东大会：
将于2024-06-14召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified (Proposal 1);
2.To approve the Company’s Third Amended and Restated 2020 Equity and Incentive Plan (the “Third Amended and Restated 2020 Plan” or the “Plan”) to increase the maximum number of shares of the Company’s common stock available for issuance under the Plan by 3,000,000 shares (Proposal 2);
3.To approve, in a non-binding advisory vote, the compensation provided to the named executive officers as described in the accompanying Proxy Statement (Proposal 3);
4.To ratify the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (Proposal 4);
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-03-11 |
详情>>
业绩披露：
2023年年报每股收益-0.7美元,归母净利润-2370.22万美元,同比去年增长51.27%
|
| 2023-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.58美元,归母净利润-1919.36万美元,同比去年增长46.58%
|
| 2023-04-28 |
股东大会：
将于2023-06-16召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified (Proposal 1);
2.To ratify the selection of Marcum LLP as LifeMD’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (Proposal 2);
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-04-29 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified
2.To approve an amendment to the Company’s 2020 Equity and Incentive Plan (the “2020 Plan”) to increase the maximum number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares
3.To ratify the selection of Friedman LLP as LifeMD’s independent registered public accounting firm for the fiscal year ending December 31, 2022
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-12 |
股东大会：
将于2021-06-24召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified (Proposal 1);
2.To approve an amendment to the Company’s 2020 Equity and Incentive Plan (the “2020 Plan”) to increase the maximum number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares (Proposal 2);
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying Proxy Statement (Proposal 3).
4.To recommend, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of the Company’s named executive officers (Proposal 4);
5.To ratify the selection of Friedman LLP as LifeMD’s independent registered public accounting firm for the fiscal year ending December 31, 2021 (Proposal 5);
6.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-02-01 |
复牌提示：
2021-02-01 10:18:14 停牌，复牌日期 2021-02-01 10:23:14
|
| 2020-12-07 |
股东大会：
将于2021-01-08召开股东大会
会议内容 ▼▲
- 1.Approving the Conversion Labs, Inc. 2020 Equity and Incentive Plan;
2.Ratifying the January 21, 2020 amendment to the Company’s Certificate of Incorporation to authorize the creation of blank check preferred stock, par value $0.0001 per share, the subsequent filing of the August 27, 2020 filing of the Certificate of Designations of Series B Convertible Preferred Stock, and the subsequent August 31, 2020 issuance of 3,500 shares of Series B Preferred Stock (collectively, the “Series B Actions”);
3.Acting on such other matters as may properly come before the meeting or any adjournment thereof.
|